OptimizeRx (OPRX) Cost of Revenue (2013 - 2026)

OptimizeRx's Cost of Revenue history runs 14 years deep, the most recent figure standing at $4.7 million for Q1 2026.

• In Q1 2026, Cost of Revenue fell 5.14% year-over-year to $4.7 million; the TTM figure through Mar 2026 stood at $32.0 million (up 5.72% YoY), while the FY2025 annual figure was $35.8 million, up 9.42% from the prior year.
• Cost of Revenue came in at $4.7 million for Q1 2026 at OptimizeRx, down from $8.1 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $10.6 million in Q2 2025 to a low of $4.7 million in Q1 2026.
• A 5-year average of $7.2 million and a median of $7.1 million in 2024 frame the typical range for Cost of Revenue.
• On a YoY basis, Cost of Revenue climbed as much as 48.56% in 2025 and fell as far as 33.41% in 2025.
• OptimizeRx's Cost of Revenue stood at $7.2 million in 2022, then soared by 46.22% to $10.5 million in 2023, then fell by 2.23% to $10.3 million in 2024, then declined by 20.93% to $8.1 million in 2025, then plunged by 41.9% to $4.7 million in 2026.
• According to Business Quant data, Cost of Revenue over the past three periods registered $4.7 million, $8.1 million, and $8.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison